Kalaris Therapeutics grants director 9,000 stock options
Kalaris Therapeutics director Anthony P. Adamis received a new stock option grant covering 9,000 shares of common stock.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Kalaris Therapeutics director Anthony P. Adamis received a new stock option grant covering 9,000 shares of common stock. The option has an exercise price of $4.72 per share and expires on June 2, 2036.
The shares underlying the option are scheduled to vest in full on the earlier of June 3, 2027 or the company’s 2027 annual meeting of stockholders, subject to continued service. Following this grant, Adamis holds 9,000 derivative securities linked to common stock directly.
Insider Trade Summary
Grant/Award: 9,000 shares
Grant/Award
1 txn
Insider
ADAMIS ANTHONY P
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 9,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 9,000 options (Direct)
Footnotes (1)
- F1. The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.
Key Figures
Option shares granted: 9,000 shares
Exercise price: $4.72 per share
Expiration date: June 2, 2036
+2 more
5 metrics
Option shares granted
9,000 shares
Stock option award to director on June 3, 2026
Exercise price
$4.72 per share
Stock option strike price
Expiration date
June 2, 2036
Option term end date
Underlying shares
9,000 shares
Common stock underlying the option
Post-grant derivative holdings
9,000 options
Total derivative securities held after transaction
Key Terms
Stock Option, exercise price, expiration date, vesting, +1 more
5 terms
Stock Option financial
"The option was granted on June 3, 2026."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion_or_exercise_price: 4.7200"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-02T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"shares underlying the option are scheduled to vest in full"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Kalaris Therapeutics (KLRS) director Anthony P. Adamis report on this Form 4?
Anthony P. Adamis reported receiving a stock option grant for 9,000 Kalaris Therapeutics common shares. The option was awarded as equity compensation with no cash purchase, giving him the right to buy shares later at a fixed exercise price.
What is the exercise price and expiration date of the KLRS stock option grant?
The stock option has an exercise price of $4.72 per share and expires on June 2, 2036. This means Adamis can choose to buy up to 9,000 shares at $4.72 any time before that expiration, once the option is fully vested.
When do the newly granted Kalaris Therapeutics (KLRS) options vest?
The options are scheduled to vest in full on the earlier of June 3, 2027 or the date of Kalaris Therapeutics’ 2027 annual meeting of stockholders. Vesting is conditioned on Adamis’ continued service with the company through the applicable vesting date.
How many derivative securities does Anthony P. Adamis hold after this KLRS option grant?
After this grant, Adamis directly holds 9,000 derivative securities in the form of stock options linked to Kalaris Therapeutics common stock. This reflects the entire amount from the new award, as shown in the post-transaction holdings reported in the Form 4.
AI-generated analysis. How Rhea-AI works. Not financial advice.
